Using the right drug: a treatment algorithm for regular supraventricular tachycardias

Area of Science:

• Cardiology
• Electrophysiology
• Pharmacology

Background:

• Pharmacological therapy is the first-line treatment for regular supraventricular tachycardias, despite advances in catheter ablation.
• Accurate electrocardiogram (ECG) diagnosis is crucial for identifying the specific tachycardia mechanism before prescribing antiarrhythmic agents.
• Most regular supraventricular tachycardias involve the atrioventricular node, either passively (atrial tachycardias, flutter) or actively (paroxysmal junctional tachycardias).

Purpose of the Study:

• To provide a rational approach to selecting antiarrhythmic agents for regular supraventricular tachycardias.
• To integrate tachycardia mechanisms and electrophysiological findings into therapeutic decision-making.
• To outline pharmacological and interventional treatment strategies for common supraventricular tachycardias.

Main Methods:

• ECG analysis to determine tachycardia type, focusing on P wave characteristics, P-QRS relationship, and QRS alternations.
• Application of the Sicilian Gambit approach, which considers critical tachycardia components and vulnerable parameters for drug selection.
• Review of pharmacological options, including adenosine, calcium channel blockers, beta-blockers, sodium channel blockers, and potassium current blockers, as well as radiofrequency ablation.

Main Results:

• Intravenous adenosine is the preferred agent for acute termination of paroxysmal junctional tachycardia.
• For atrioventricular nodal re-entrant tachycardia prevention, slow pathway depressants (calcium channel blockers, beta-blockers) are effective, followed by sodium channel blockers if needed.
• Tachycardias involving accessory pathways respond to fast channel blockers; atrial tachycardias are treated with propafenone, flecainide, or sotalol; amiodarone is effective for drug-resistant cases.

Conclusions:

• The choice of antiarrhythmic therapy for supraventricular tachycardias should be guided by the specific tachycardia mechanism identified through ECG and electrophysiological studies.
• Pharmacological agents targeting specific pathways (slow vs. fast) or ion channels offer effective treatment options.
• Radiofrequency ablation is a viable and increasingly utilized alternative for drug-resistant or drug-intolerant patients.